Short Interest in Pulmatrix, Inc. (NASDAQ:PULM) Drops By 97.4%

Pulmatrix, Inc. (NASDAQ:PULM) was the recipient of a large drop in short interest in March. As of March 15th, there was short interest totalling 400 shares, a drop of 97.4% from the February 29th total of 15,300 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average trading volume of 17,900 shares, the short-interest ratio is currently 0.0 days.

Pulmatrix Stock Performance

Shares of NASDAQ PULM traded up $0.13 during trading on Thursday, hitting $1.75. 38,150 shares of the company traded hands, compared to its average volume of 17,331. The firm has a market capitalization of $6.39 million, a price-to-earnings ratio of -0.40 and a beta of 0.95. The business’s fifty day moving average is $1.80 and its 200 day moving average is $1.91. Pulmatrix has a fifty-two week low of $1.55 and a fifty-two week high of $3.15.

Analyst Ratings Changes

Separately, StockNews.com started coverage on Pulmatrix in a report on Saturday, March 23rd. They set a “hold” rating on the stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC raised its position in shares of Pulmatrix by 7.3% during the second quarter. Renaissance Technologies LLC now owns 121,920 shares of the biotechnology company’s stock worth $560,000 after purchasing an additional 8,300 shares during the period. Citadel Advisors LLC bought a new position in shares of Pulmatrix in the second quarter valued at approximately $141,000. Mariner LLC bought a new position in shares of Pulmatrix in the fourth quarter valued at approximately $97,000. Susquehanna International Group LLP bought a new stake in Pulmatrix during the first quarter worth $73,000. Finally, Vanguard Group Inc. raised its position in Pulmatrix by 62.9% in the 4th quarter. Vanguard Group Inc. now owns 35,082 shares of the biotechnology company’s stock valued at $65,000 after buying an additional 13,548 shares during the last quarter. 11.84% of the stock is owned by institutional investors and hedge funds.

About Pulmatrix

Pulmatrix, Inc, a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.